	Application No.	Applicant(s)
	09/993,241	KAKKIS, EMIL D.
Notice of Allowability	Examiner	Art Unit
	Manjunath N. Rao, Ph.D.	1652
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to the amendment filed on 4-15-04.		
2.  The allowed claim(s) is/are 14-59.		
3. The drawings filed on 13 November 2001 are accepted by the Examiner.		
<ul> <li>4.</li></ul>		
Attachment(s)  1. ☑ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/Paper No./Mail Date  4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summa Paper No./Mail /08), 7. ☐ Examiner's Ame	Date
		Manjunath N. Rao, Ph.D. Primary Examiner Art Unit: 1652

Art Unit: 1652

## **DETAILED ACTION**

Claims 14-59 are currently pending and are present for examination.

Applicants' amendments and arguments filed on 4-15-04, have been fully considered and are deemed to be persuasive to overcome the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.

## Drawings

Drawings submitted in this application are accepted by the Examiner for examination purposes only.

## Terminal Disclaimer

The terminal disclaimer filed on 4-15-04 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of US 6585971 has been reviewed and is accepted. The terminal disclaimer has been recorded.

## Allowable Subject Matter

Claims 14-59 are allowed.

The following is an examiner's statement of reasons for allowance: Following a diligent search it was determined that the prior art neither teaches nor suggests a method of treating human disorders caused all or in part by a deficiency of alpha L-iduronidase using a purified human recombinant alpha L-iduronidase having an amino acid sequence SEQ ID NO:2 or an enzymatically portion thereof, wherein said enzyme or the enzymatic portion has a purity of greater than 99%, as claimed in claims 14-59.

Application/Control Number: 09/993,241

Art Unit: 1652

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Manjunath N. Rao, Ph.D. whose telephone number is 571-272-0939. The Examiner can normally be reached on 7.00 a.m. to 3.30 p.m. If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Ponnathapura Achutamurthy can be reached on 571-272-0928. The fax phone numbers for the organization where this application or proceeding is assigned is 703-872-9306 for regular communications and for After Final communications. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

Manjunath N. Rao May 12, 2004